Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

Bayer has received FDA approval for Lynkuet® (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause. This approval, supported by positive data from the Phase III OASIS clinical trial program, introduces a significant non-hormonal treatment option for a prevalent condition, with U.S. market availability expected in November 2025. The drug's unique mechanism and broad indication position it as a key new product in Bayer's women's healthcare portfolio.

Analysis

Bayer has secured FDA approval for Lynkuet® (elinzanetant) 60mg capsules, a first-in-class dual neurokinin 1 and 3 receptor antagonist, for treating moderate to severe hot flashes due to menopause. This approval, effective October 24, 2025, marks a significant advancement as Lynkuet is the first and only non-hormonal therapy of its kind. U.S. market availability is expected in November 2025, positioning it as a new core product in Bayer's women's healthcare portfolio.

The FDA decision is underpinned by robust data from the Phase III OASIS clinical trial program (OASIS 1, 2, and 3), which demonstrated Lynkuet's efficacy in reducing the number and severity of moderate to severe hot flashes at weeks 4 and 12. This new treatment option addresses a prevalent condition, offering healthcare providers a potential first-line therapy for women seeking relief from disruptive menopausal symptoms. Its unique mechanism of action differentiates it from existing treatments.

While the approval is positive, investors should note the listed serious side effects, including CNS effects, increased liver blood test values, and risks of pregnancy loss, necessitating careful patient selection and monitoring. Bayer's commitment to accessibility via programs like LASS and the Patient Assistance Foundation indicates a strategic focus on broad market penetration. Global commercialization is underway, with prior approvals in several countries and pending EU review.

Key Decisions for Investors

• Monitor Lynkuet's initial market penetration and sales performance post-November 2025 launch, particularly given its first-in-class, non-hormonal status in a significant market.
• Evaluate Bayer's commercial strategy for Lynkuet, including the effectiveness of patient access programs and global expansion efforts, against competitive landscape developments.
• Assess any emerging real-world safety data or patient adherence trends, especially concerning the noted serious side effects, as these could influence long-term adoption and market share.